Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Essential Hypertension Clear all
Not yet recruiting Phase 3 Interventional

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

NCT07083765
View directory record Official record
Conditions
Hypertension, Hypertension,Essential
Interventions
Dehydrated Alcohol Injection, USP, Sham procedure
Drug · Procedure
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 21, 2026, 6:10 PM EDT
Recruiting Not applicable Interventional

Sleep Promotion and Pediatric Hypertension

NCT06642246
View directory record Official record
Conditions
Insufficient Sleep, Hypertension
Interventions
Intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 6:10 PM EDT
Active, not recruiting Not applicable Interventional Results available

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426
View directory record Official record
Conditions
Hypertension, Vascular Diseases
Interventions
The Paradise® Renal Denervation Ultrasound System, Sham Procedure
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 6:10 PM EDT
Recruiting Not applicable Interventional

Dose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function

NCT07109739
View directory record Official record
Conditions
Systolic Hypertension, Brachial Artery Flow-mediated Dilation
Interventions
POWERbreathe K5
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 21, 2026, 6:10 PM EDT
Recruiting No phase listed Observational

Childhood-Onset Essential Hypertension Natural History Study

NCT06778239
View directory record Official record
Conditions
Hypertension, Essential Hypertension
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions

NCT01012687
View directory record Official record
Conditions
Essential Hypertension
Interventions
perindopril erbumine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Implementing Hypertension Screening Guidelines in Primary Care

NCT03480217
View directory record Official record
Conditions
Hypertension,Essential, White Coat Hypertension
Interventions
Multifaceted Implementation Strategy, Usual care
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 1 Interventional

Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure

NCT00099476
View directory record Official record
Conditions
Hypertension
Interventions
Effects of dark chocolate
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

NCT00591578
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil, Valsartan
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
77
States / cities
Huntsville, Alabama • Glendale, Arizona • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

NCT00219128
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

NCT00549770
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 21, 2026, 6:10 PM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Effects of a Mindfulness Intervention on Health Outcomes in Individuals With Hypertension

NCT07679984
View directory record Official record
Conditions
Hypertension, Essential (Primary) Hypertension
Interventions
Mindfulness in Motion
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

NCT00355589
View directory record Official record
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2011 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional

A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia

NCT00171093
View directory record Official record
Conditions
HYPERTENSION, HYPERCHOLESTEROLEMIA
Interventions
valsartan + simvastatin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

NCT02412761
View directory record Official record
Conditions
Essential Hypertension
Interventions
Lisinopril, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Years to 22 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

NCT00362115
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
46
States / cities
Huntsville, Alabama • Ozark, Alabama • Mesa, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00695955
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Ozark, Alabama • Tallassee, Alabama • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 21, 2026, 6:10 PM EDT
Completed Phase 2 Interventional

Uric Acid in Essential Hypertension in Children

NCT00288184
View directory record Official record
Conditions
Essential Hypertension
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 21, 2026, 6:10 PM EDT